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1. Introduction
Optimizing balance between therapeutic efficacy and the occurrence of adverse events is the
main goal of individualized medicine. This takes even more importance in narrow therapeutic
index drugs such as immunosuppressants. These drugs are highly effective in preventing acute
graft rejection but tacrolimus, cyclosporine and mycophenolic acid show highly variable
pharmacokinetics and pharmacodynamics. Still nowadays the fragile equilibrium between the
risks and benefits of immunosuppression makes the management of immunosuppressive
pharmacotherapy a challenge.
Therapeutic drug monitoring (TDM) is an essential and indispensable instrument for calci‐
neurin inhibitors dosing, reducing the pharmacokinetic component of variability by control‐
ling drug blood concentrations. But TDM is only possible once the drug is administered and
steady state and patient’s compliance are achieved, so complementary strategies are needed.
Moreover, despite correct TDM, it may take several days or even weeks to reach target blood
concentrations. For many patients this time periods are not appropriate in order to achieve
sufficiently high concentrations to prevent graft rejection or adverse reactions or, on the other
hand, without exposing the patient to excessive toxicity. In this sense, Pharmacogenetics is an
interesting approach, helpful to manage immunosuppressant drugs. Changes in expression
or function of proteins and enzymes involved in drug transport, metabolism or mechanism of
action will cause changes in drug’s absorption, metabolism and distribution and, therefore,
can lead to changes in the response and toxicity of the treatment. Characterization of these
genetic variants, mainly Single Nucleotide Polymorphisms (SNPs), can help to establish
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effective doses and to minimize adverse effects. Many publications, including our own, have
found statistically significant correlations between (SNPs) and tacrolimus and/or cyclosporine
dose-corrected blood levels. There are also works correlating certain variants in SNPs with
safety and efficacy of the treatment. Even some researchers, working groups and consortia
recommend guidelines for initial dosing adjust regarding this SNPs.
Pharmacogenetic  tests  are becoming cheaper every day,  so the cost  of  performing these
assays  is  getting  more  assumable,  especially  when  clinically  relevant  complications  are
demonstrated.  The incorporation of  pharmacogenetic  studies  to  the real  clinical  practice
will  depend  on  the  creation  of  well-designed  sets  of  SNPs  that,  in  a  cost-effectiveness
manner,  could correlate  clinical  complications  with genotypes,  taking into  consideration
the whole and complicated treatment in polymedicated patients. Many results contribute
to  highlight  the  need  of  prospective  controlled  studies,  with  pharmacogenetic  analysis
prior to transplantation.  This will  probably be the critical  point for the regulatory agen‐
cies  to  settle  the  most  relevant  polymorphisms  as  validated  biomarkers  to  be  widely
used in the clinical transplantation setting.
For all this reasons, our aim in this chapter is to provide an easy explanation about what a
polymorphism is and an updated view of the most relevant SNPs with evidence of their
implication in safety and efficacy of immunosuppressive treatment in renal transplantation.
The final goal is to give a summary from basic knowledge to concrete examples that help to
improve the medical doctors’ knowledge of the clinical impact of Pharmacogenetics in their
daily practice.
2. Personalized medicine and pharmacogenetics
The term “Personalized Medicine” was not  long ago some “scifi”  concept,  just  express‐
ing the best wishes of the scientific community with an aim of adjusting the pharmaco‐
therapy  as  best  as  possible  to  each  single  patient.  However,  in  the  last  years  we  have
seen real advances in this area that have brought to the real clinical practice in most of
the “first  world” countries,  a  set  of  new analysis  under  the  same principle:  offering an
individualized therapy to each different patient.
In order to understand this new approach in medicine and put it into practice, we necessarily
have to take genetics in consideration, and particularly, we have to pay attention to the
individual differences that make each patient respond in a different way to a given pharma‐
cological treatment. Here, we arrive to the concepts of Pharmacogenetics and Pharmacoge‐
nomics, that can be heard in more and more places each day. They are, and for sure will be,
components to be considered in the medical practice. We can define them in many ways, and
traditionally they have been employed interchangeably although there are differences between
them. They are different but complementary disciplines. The European Medicines Agency,
EMA, takes their definitions from The International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for Human Use (ICH), this is a project with
regulatory authorities from Europe, Japan and USA, together with experts from pharmaceut‐
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icals that discusses technical and scientific aspects about the products registries. One of its aims
is to reach a better harmonization in the interpretation and application of technical guides and
requirements for the registries. ICH defines Pharmacogenomics as the study of variations in
DNA and RNA characteristics regarding the response to drugs and it defines Pharmacoge‐
netics as a subset inside pharmacogenomics, that studies the variations in the DNA sequence
regarding the response to drugs [1-5].
There is another term that is also frequently found: biomarker, genetic or genomic biomarker,
whose definition is “a measurable characteristic of DNA and/or RNA which is an indicator of
a biological process that can be normal, pathogenic and/or a response to a therapeutic (or other
kind) intervention. A genomic biomarker could be, for instance, the measuremente of a gene
expression or of its regulation. It can consist in one or more DNA and/or RNA characteristics,
as for instance, in DNA, its single nucleotide polymorphisms (SNPs); the variability in the
repetition of short sequences; the haplotypes; DNA modifications as methilation; the deletions
or insertions of a single nucleotide; the copy number variation; or the cytogenetic rearange‐
ments as translocations, duplications, deletions or inversions. Regarding RNA, it could be a
particular trait of its sequence; the levels of expression; the processing (as splicing and editing);
or the levels of microRNAs. A deeper explanation of some of these terms will be done in the
next paragraph.
The aim of pharmacogenomics is to identify the most important genetic elements in the
instauration and/or evolution of a pathological process in order to create new strategies for
drug evaluation and optimization of the drug development process. These are usually high
throughput studies, regarding the simple number and statistical signification but also very
exigent with the study subject: the final goal is finding correlation with the disease at a genomic
level, not with one single nucleotide but with genes or groups of related genes instead. On the
other side, pharmacogenetics studies the influence of genetic factors on the activity of a drug,
making attention in concrete changes inside a gene that somehow has already been postulated
as a candidate gene, by previous knowledge or by pharmacogenomic studies. Subject of
pharmacogenetic studies are especially, the variants in genes related with transport and
metabolism of drugs, with the aim that specific drugs can be given to specific groups of
genetically defined (or “stratified”) patients [6, 7].
To summarize, pharmacogenetics has to be considered as one of the mainstays of personalized
medicine, which will let us correlate good or bad response to a drug in a specific population
with genetic aspects. It will also let us know which drugs will offer greater therapeutic benefit
or lower risk of adverse reactions development for a given population.
3. What are genetic polymorphisms?
We also must review some other basic concepts in genetics and, extensively, pharmacogenetics
in order to understand the following information. The most relevant one is Polymorphism,
which is defined as a mendelian monogenic character that appears in the population with the
presence of more than one allele in the same genetic locus. Applying the term to pharmaco‐
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genetics, it makes reference to the different alleles or variants of a gene related to a drug
interaction with the body. The frequency of the less common allele in the population must not
be higher than 1%. The two main groups of genetic polymorphisms are Single Nucleotide
Polymorphisms (SNPs) and Lenght Polymorphisms (repetitions of nucleotide groups). The
first group represents 90% of genetic variability in our genome, and each nucleotide change
appears approximately in 1 every 1000 nucleotides. Length polymorphisms represent more
extensive changes in the DNA sequence and approximately are the remaining 10% of poly‐
morphic variability in our genomes.
The NCBI SNP database (www.ncbi.nlm.nih.gov/snp) contains all the SNPs described, ar‐
ranged by their  Reference number,  which names all  SNPs starting with the letters  “rs“,
followed  by  a  number  code,  but  also  including  some  classical  names  that  had  already
been given to some SNPs. By clicking on a SNP code, one can get more information and
several links, one of them is called “diversity“ and shows the different allele frequencies
found  depending  on  the  study  and  especially,  depending  on  the  sample’s  ethnicity.
There are polymorphic sites with allelic frequencies quite well conserved amongst differ‐
ent ethnicities, but others have relevant differences and we must always pay attention to
this point.
The exact  biological  difference  in  meaning between “polymorphism” and “mutation” is
not always clearly defined.  The term "mutation" is  classically associated with pathologi‐
cal significance, while "polymorphism" usually refers to a genetic change without health
consequences.  The problem is that “polymorphism” has also been employed to describe
mostly any newly described genetic  variant,  without having studied it  enough to know
if  it  has  a  pathological  consequence  or  not.  The  international  research  project  1000  ge‐
nomes (www.1000genomes.org) has been a great effort to sequence the whole genome of
a  thousand different  people,  so  we  are  still  attending  to  well  quantified  frequencies  of
genetic variants, that in some cases will still be measured in not sufficient people and so,
knowing  exactly  the  population  frequencies  of  all  our  genome  variants  is  still  a  chal‐
lenge,  moreover due to the fact  that the frequencies vary amongst different human eth‐
nicities. In conclusion, we must be cautious when interpreting the term “polymorphism”
and not assume that it is just a genetic change without any biological consequences, as it
may has not been well characterized yet.
The genetic variants that can influence the behavior of a drug in the body, are mainly re‐
lated to the interaction of the drug with the receptor/ligand involved in their pharmaco‐
logical  action  and/or  with  the  systems  involved  in  its  pharmacokinetic  process  of
absorption,  distribution,  metabolism  and  excretion.  So,  transport,  metabolism  and  drug
target genes are the three groups of genes whose polymorphisms are of interest in phar‐
macogenetics. In a very simplistic way, an individual carrying a significant polymorphic
variant will  suffer from different effects from those suffered by the individuals carrying
the “normal” variant at  the same polymorphic site,  but just in the case of being treated
with  the  particular  drug  affected  by  that  variant.  If  that  individual  is  not  treated  with
that drug, he may not manifest any effects related to that polymorphism.
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Other relevant concepts to understand pharmacogenetics are Haplotipe and Linkage Dise‐
quilibrium (LD). Haplotype refers to those alleles of a chromosome, or part thereof, which are
physically close and that tend to be inherited together. In our field, it is especially important
that more and more frequently the research is focused not on single SNPs, but on combinations
of them, forming haplotypes. Although many research has been simplified, studying SNPs
analyzed one by one, the real biological significance of these genetic changes must be seen in
the resulting effect of groups of SNPs, since the individual effects of each one can be enhanced,
reduced or offset by the effects of others. In addition, the linkage disequilibrium, is the situation
in which some alleles are present together in a higher frequency than expected, due to its close
location in the chromosomes. This is important in SNPs research, since one can study a SNP
that is well know and easy to determine, instead of studying another SNP linked to the first,
that is more difficult to assess, and the results can be correlated. For instance, in some cases
one SNP, with not known biological significance, is correlated with certain clinical conse‐
quence, and after a deeper research it is found that actually that first SNP is in fact in linkage
disequilibrium with another SNP, unknown or non studied before, that is directly related to
that clinical consequence.
In relation to these concepts, we can now understand that SNPs that have not got a clearly
studied functional meaning, for example they do not alter the amino acid sequence or are not
regulatory in intronic regions, are usually included in research projects. Maybe these SNPs are
linked to others that are not taken into consideration but that do produce a direct effect on the
gene product. These studies will be completed when information of LD blocks, provided for
instance in public consultation databases as HapMap (www.hapmap.org), would be included.
These final integrative approaches require powerful statistical and in silico analysis, correlating
the large amount of information obtained.
4. Genes and drugs
After understanding the basic concepts, we can now enter the approach to the best known
gene-drug relationships. There are currently different reference sources that help us in this
welter of information, such as the aforementioned HapMap project, the SNP database of NCBI
and, to our knowledge, the best pharmacogenetics website which is the Pharmacogenomics
Knowledge Base, PharmGKB (www.pharmgkb.org). This latter website, is a very intuitive way
of learning and consulting about gene-drug relationships, by performing searches based on
gene, SNP, drug or disease; with research and clinical information, and lots of links to external
related sites. There we can find a table of the “well-known drug-gene pharmacogenomics
associations” which represents the drugs whose relationship with some polymorphic gene has
been clearly defined in the literature and is academically accepted, based on extensive reviews
of all available information.
The United States Food and Drug Administration (FDA, www.fda.gov) also publishes a list
of drugs where a genetic test is recommended or mandatory for the drug administration,
explaining which section of the drug label has the genetic-related information.
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DRUG BIOMARKER DRUG BIOMARKER
Abacavir HLA-B*5701 Irinotecan UGT1A1
Aripiprazole CYP2D6 Isosorbide and Hydra-lazine62 NAT1, NAT2
Arsenic Trioxide PML/RARα Ivacaftor CFTR
Atomoxetine CYP2D6 Lapatinib Her2/neu
Atorvastatin LDL receptor Lenalidomide Chromosome 5q
Azathioprine TPMT Letrozole ER &/ PgR receptor
Boceprevir IL28B Maraviroc CCR5
Brentuximab Vedotin CD30 Mercaptopurine TPMT
Busulfan Ph Chromosome Metoprolol CYP2D6
Capecitabine DPD Modafinil CYP2D6
Carbamazepine HLA-B*1502 Nilotinib Ph Chromosome, UGT1A1
Carisoprodol CYP2C19 Nortriptyline CYP2D6
Carvedilol CYP2D6 Omeprazole CYP2C19
Celecoxib CYP2C9 Panitumumab EGFR, KRAS
Cetuximab EGFR, KRAS Pantoprazole CYP2C19
Cevimeline CYP2D6 Paroxetine CYP2D6
Chlordiazepoxide and
Amitriptyline
CYP2D6 Peginterferon alfa-2b IL28B
Chloroquine G6PD Perphenazine CYP2D6
Cisplatin TPMT Pertuzumab Her2/neu
Citalopram CYP2C19, CYP2D6 Phenytoin HLA-B*1502
Clobazam CYP2C19 Pimozide CYP2D6
Clomiphene Rh genotype Prasugrel CYP2C19
Clomipramine CYP2D6 Pravastatin ApoE2
Clopidogrel CYP2C19 Propafenone CYP2D6
Clozapine CYP2D6 Propranolol CYP2D6
Codeine CYP2D6 Protriptyline CYP2D6
Crizotinib ALK Quinidine CYP2D6
Dapsone G6PD Rabeprazole CYP2C19
Dasatinib Ph Chromosome Rasburicase G6PD
Denileukin Diftitox CD25 Rifampin, Isoniazid, and
Pyrazinamide
NAT1; NAT2
Desipramine CYP2D6 Risperidone CYP2D6
Dexlansoprazole CYP2C19, CYP1A2 Sodium Phenylacetate and
Sodium Benzoate
UCD (NAGS; CPS; ASS; OTC; ASL;
ARG)
Dextromethorphan and
Quinidine
CYP2D6 Sodium Phenylbutyrate UCD (NAGS; CPS; ASS; OTC; ASL;
ARG)
Diazepam CYP2C19 Tamoxifen ER receptor
Doxepin CYP2D6 Telaprevir IL28B
Drospirenone and Ethinyl
Estradiol
CYP2C19 Terbinafine CYP2D6
Erlotinib EGFR Tetrabenazine CYP2D6
Esomeprazole CYP2C19 Thioguanine TPMT
Everolimus Her2/neu Thioridazine CYP2D6
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DRUG BIOMARKER DRUG BIOMARKER
Exemestane ER &/ PgR receptor Ticagrelor CYP2C19
Fluorouracil DPD Tolterodine CYP2D6
Fluoxetine CYP2D6 Tositumomab CD20 antigen
Fluoxetine and Olanzapine CYP2D6 Tramadol and Acetaminophen CYP2D6
Flurbiprofen CYP2C9 Trastuzumab Her2/neu
Fluvoxamine CYP2D6 Tretinoin PML/RARα
Fulvestrant ER receptor Trimipramine CYP2D6
Galantamine CYP2D6 Valproic Acid UCD (NAGS; CPS; ASS; OTC; ASL;
ARG)
Gefitinib EGFR Vemurafenib BRAF
Iloperidone CYP2D6 Venlafaxine CYP2D6
Imatinib C-Kit, Ph Chromosome, PDGFR,
FIP1L1-PDGFRα
Voriconazole CYP2C19
Imipramine CYP2D6 Warfarin CYP2C9, VKORC1
Indacaterol UGT1A1
Table 1. FDA Pharmacogenomic biomarkers in drug labels (adapted from www.fda.gov)
There is certainly a lot of work done, but there is still much to do. Today, there are many
publications and many research articles in the area, and the field is growing exponentially, but
most of these studies reflect data from very specific conditions, where sets of patients with
convenient features and sometimes far from the clinical reality, where included. It is necessary
to validate the actual utility of pharmacogenetics in routine medical practice with serious, well-
designed studies [8].
4.1. Genes and drugs in transplantation
In the pharmacogenetics of transplantation, as in other therapeutic areas, three groups of genes
specifically involved in the response to immunosuppressive therapy have been identified: the
genes encoding drug transporter proteins, inward or outward of the cells; the genes encoding
metabolic enzymes involved in drug biotransformation and, finally; those encoding receptors
or drug targets. Although the great majority of immunosuppressive drugs are transported and
metabolized by a limited set of enzymes which mostly are known genes, the interpretation of
the results observed in transplanted patients is complicated in many times. One reason for this
is that these patients are highly subjected to polytherapy, and so interactions, both pharma‐
cokinetic and pharmacodynamic, may have great significance and may condition the response
to treatment. Another important aspect to consider when interpreting the observed response
is the fact that each patient actually contains two different genetic entities: the donor and the
recipient. This phenomenon is particularly relevant when the transplanted organs are the liver
or the kidney. In these types of transplantation, it must be considered that the drugs admin‐
istered to the recipient will be metabolized or excreted by the transplanted organ from the
donor. In fact, more and more studies in transplantation pharmacogenetics consider both the
donor and recipient genotypes to evaluate the response to treatment [9-12].
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Moreover, one of the main problems of pharmacogenetic studies is the difficulty to recruit the
number of patients needed to achieve sufficient statistical power and demonstrate conclusively
the existence of significant clinically relevant differences according the different genotypes,
that is, according to the different alleles or variants of a polymorphic site. This is due to the
uneven distribution of allele frequencies in the population, which makes it difficult to collect
a large enough number of individuals to study minor genotypes. Furthermore, the distribution
of allelic frequencies in some genes varies according to ethnicity so, for instance, the expected
frequencies of each allele of a polymorphic site in the Caucasian population are not the same
as in the Asian. The expected effects of each allelic variant are presumably the same, but the
ease for recruiting different genotype patients is not.
Figure 1 shows, in summary, an integrator scheme with the best known genes encoding
transporter proteins and enzymes involved in the metabolism of several drugs commonly used
in transplantation.
Figure 1. Integrative scheme of pharmacogenetic genes related to transport and metabolism of immunosuppressive
drugs for transplantation. (Adapted from ref. 13, ©Astellas Pharma S.A. y Master Line & Prodigio S.L.). The drawing
shows a broad view of the location and influence of metabolic enzymes and transporters on the main immunosup‐
pressive drugs used in transplantation. The integrated view of many of the genetic factors that influence the achieve‐
ment of therapeutic and stationary blood levels, should allow a better interpretation of pharmacogenetic data and
also, help improve the safe and effective use of medication.
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4.2. Pharmacogenetic examples in renal transplantation
Pharmacogenetic information of immunosuppressants in renal transplantation is mainly
related to Tacrolimus, Cyclosporine and Mycophenolic Acid. Sirolimus, Everolimus and
Corticoids are also being studied but to a much lesser extent, so we will focus here on the most
consolidated conclusion about the first three drugs.
The first two, being both Calcineurin Inhibitors (CNI), share their mechanism of action and so,
share transporters, metabolism enzymes and targets and therefore, they also share pharma‐
cogenetic results in most of the cases. The fact that they are both subject of a controlled
therapeutic drug monitoring, with “in some way” standardized blood measuring methods,
has allowed the publication of many works dealing with correlations between drug levels and
polymorphisms [14-23]. To a lesser extent, there are also many works correlating drug adverse
effects with SNPs [24-28]. The therapeutic drug monitoring of mycophenolic acid is not as
followed as for CNIs, as there is not such a clear consensus about the effects of different blood
levels in the possible drug related toxicity. However, many efforts have also been done in the
pharmacogenetic studies of this drug [29-36], as it is widely employed in combination with
tacrolimus or cyclosporine.
The most consensuated genes regarding polymorphic effects on these three immunosuppres‐
sants are shown in table 2.
DRUG GENE SNP Effect
Tacrolimus
Cyclosporine
ABCB1
transport
rs1045642 C>T;
3435 C>T
C: higher transporter activity, less drug absorption
T: lower transporter activity, more drug absorption
CYP3A5
metabolism
rs776746 A>G;
*1 (A), *3 (G)
Allele *1 carriers have functional enzyme and require higher drug doses to reach
target levels. Allele *3 carriers have nonfunctional allele, the enzyme is not
metabolizing the drug, so they need lower doses
CYP3A4
metabolism Implications not clearly defined
Mycophenolic
Acid
UGT1A9
metabolism
-275 T>A
-2152 C>T
-275A and -2152T: Increased gene expression, lower exposition to MFA and acute
rejection in patients with fixed dose MFA+Tac
ABCC2
transport
C-24T
C3972T Implications not clearly defined
IMPDH1
target rs2278293 Higher risk of leucopenia, lower risk of BPAR
IMPDH2
target 3757 T>C
C: higher IMPDH activity, higher incidence of BPAR (biopsy-confirmed acute
rejection)
SLCO1B1
transport *5 Implications not clearly defined
Table 2. Most studied SNPs related to Tacrolimus, Cyclosporine and Mycophenolic Acid in Renal Transplantation.
As shown in the table, even in these SNPs that are the most extensively studied, the clinical
implications are not always well established. Many more other SNPs are currently under
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research consideration, being what we can call “candidates” to have a clinical meaning.
Virtually, every polymorphism of a gene implicated in a drug’s route of transport, metabolism
or mechanism of action is a potential candidate to be investigated. Especially if the polymor‐
phism is known to have a biological consequence on the gene product as for instance, if it is a
polymorphism producing a premature STOP codon or a relevant aminoacid change.
Returning to the SNPs in table 2, we will pay attention now to ABCB1 and CYP3A5 most rele‐
vant results. In Figure 2, we can see a schematic example of what happens in the intestine epi‐
thelial cells, according to the SNP rs1045642 C>T (also known as 3435 C>T) in ABCB1 gene. This
gene codes for glicoprotein P (gp-P)which is an adenosine triphosphate-dependent transport‐
er, that pumps many endogenous substances and also xenobiotics, as drugs, outside of the cell.
It is specifically expressed in the intestine, liver and kidney, amongst others, and also in several
types of leukocytes so it is postulated to function as a protective barrier by actively extruding
different compounds out of the cell, into the gut lumen, bile or urine. The expression of ABCB1
in the kidney plays an important role in the renal elimination of metabolic waste products and
toxins. It seems like after renal injury, ABCB1 expression is upregulated, which may represent
an adpative response in the renal regeneration process [37]. Parallelly, it has been shown that
treatment with CNI induces ABCB1 expression both in vivo and in vitro, which could serve to
protect the kidney from the injurious effects of CNIs by facilitating their extrusion. If we add to
this, the polymorphic influence shown in figure 2, we can better understand that a failure to ad‐
equately upregulate ABCB1 expression or a constitutively low expression in renal cells (as for
instance due to 3435 TT variant), could lead to intrarenal accumulation of CNIs and predispose
patients to the occurrence of CNI-related nephrotoxicity [38].
Specifically, in renal transplantation, it has been found a correlation between the genotype of
donors TT at this SNP and cyclosporine nephrotoxicity [40], while no consistent relationships
were found according to the same SNP in the recipient.
Regarding CYP3A5, there is more statistical evidence, especially regarding its impact on CNIs
blood levels and these findings have led to some clinical recommendations, as we will see in
the next paragraph. Inside the CYP 450 family, the CYP3A subfamily metabolizes more than
50% of all drugs that are currently in use [41]. CYP3A5 is expressed in the small intestine and
the liver but also in the kidney.
One of the most relevant studies regarding CYP3A5 SNP rs776746 A>G (*1 (A), *3 (G)) is the
one published by Thervet et al. in 2010 [23]. It is a prospective randomized clinical trial that
demonstrates the usefulness of this SNP determination before the first tacrolimus dose in renal
transplantation. In this study, the pharmacokinetic parameters were correlated with the
recipients’ genotype and two arms were constructed, one with the classical management of
the patients, adjusting tacrolimus doses according to TDM; and the second arm, where the
initial dose was chosen according to a previous genetic analysis to include the patients in
“CYP3A5 expresser” or “CYP3A5 non-expresser” cathegories. The expressers were given an
initial 0.25mg/kg dose and the non-expressers 0.15mg/kg. As a result, the genetically driven
dosage was associated with an earlier obtention of tacrolimus concentrations inside the
therapeutic range, also with fewer dose adjustments. Also, it was demonstrated that in the first
arm, patients with genotype *1 needed double tacrolimus dose to reach the target levels, as
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compared to those patients that were *3. Moreover, there are also consistent data in pediatric
renal transplant recipients [42].
Figure 2. Influence of the functional activity of glycoprotein-P (transporter in apical membrane) in the transport of
tacrolimus (green stars) in the intestine epithelium. The diagram shows the different degree of drug absorption due to
variations in ABCB1/MDR1 polymorphic site rs1045642. Individuals with TT variant have a decreased transporter activ‐
ity and hence greater absorption efficiency. CC variant causes more expulsion out of the cell, which decreases absorp‐
tion. (Figure adapted from ref. 39)
Just as a final remark, we cannot forget to mention the great importance of drug interactions.
Although it is not the subject of this chapter, and we are not going to get into it, we just wanted
to point here that drug interactions can mask even genetic variations in the clinical practice.
5. Regulatory aspects and final conclusions
5.1. Clinical practice recommendations
We have only seen, with a little bit of detail, two of the SNPs that could actually be influencing
the pharmacologic treatment in renal transplantation. And with these two SNPs, only one,
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CYP3A5 rs776746, has reached some kind of clinical recommendations. These have not been
adopted by any of the regulatory agencies FDA nor EMA, but they already have a strong
evidence as to be considered by expert doctors in the area.
The 3rd European Science Foundation- University of Barcelona (ESF-UB) Conference in
Biomedicine on Pharmacogenetics and Pharmacogenomics, held in June 2010 in Spain,
published a summary of their practical recommendations [43] which include the explained
tacrolimus results. They recommend CYP3A5 rs776746 genotyping prior to grafting as it could
help to reach steady state plasma tacrolimus concentrations earlier, and therefore prevent
overdose (risk of nephrotoxicity) or underdose (risk of acute graft rejection). This recommen‐
dation is mainly based on Thervet’s publication [23] and suggests the introduction of tacroli‐
mus at 0.15 mg/kg/day when the recpient’s genotype is *3/*3, at 0.20 mg/kg/day when it is *3/
*1, and at 0.25 mg/kg/day when it is *1/*1; always taking into consideration that the patients
will also require the regular TDM.
The Dutch Pharmacogenetics Working Group Guideline from the Royal Dutch Pharmacists
Association have also evaluated therapeutic dose recommendations for tacrolimus based on
our CYP3A5 SNP [44] and have found evidence to support an interaction between the drug
and the gene. However, they do not make dosing recommendations adducing that in dutch
transplantation hospitals, the tacrolimus dose is titrated in response to TDM.
5.2. What is a meta-analysis and what is the need of them?
The number of publications is increasing every day in an accelerated manner to limit the ability
of researchers and clinicians to assess critically and to assume the results of the studies. This,
added to the fact that the knowledge about something is not born due to a single article, but
to the integration of many, requires conducting systematic reviews of available evidence, of
which there are two types:
• Qualitative systematic reviews, where evidence is presented descriptively
• Quantitative systematic reviews or meta-analyses, which combine the results in a single
endpoint and determine the causes of the variations between studies.
Meta-analysis is a summary of different qualitative and quantitative studies (usually random‐
ized controlled trials) that evaluate one aspect whose results are combined using statistic
resources to determine the directionality of the effect and the causes of variability between
studies. It is the gold standard tool to assess the consistency of an evidence in the effect of a
particular intervention, especially when studies are heterogeneous and discordant, when
studies evaluating outcomes affect a low number of patients (as it happens when reporting
adverse events), when conducting new clinical trials is expensive or when we want to know
the existence of patient subgroups responding differently to the intervention analyzed.
• In this way the results allow us to:
• Plan future clinical trials on a related topic.
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• Quantify publication bias (as many studies fail to be published because their results are not
significant) [45, 46].
• Provide evidence to generate new hypotheses.
• Decide whether further clinical trials are needed on the subject.
• Help to document the approval of the use of interventions by regulatory agents and also
expand the knowledge to academics.
Calculate the sample size needed for future clinical trials about a similar topic.
Conducting such studies is cumbersome, it is really time-consuming, requires complex
methodological knowledge and its performance is not free of trouble. The main difficulties are
the presence of a small number of previously existing studies, the fact that the selected studies
to be analysed are usually very heterogeneous and difficult to be combined, and in many of
them the necessary information is absent or with low methodological quality. However, meta-
analysis studies are low-cost and have high impact.
However, we must be careful as the name "meta-analysis" does not ensure a quality review
and readers should critically evaluate it before accepting its results, for which there are
currently accessible guides [47, 48]. Its validity largely depends on the quality of the included
studies and the absence of bias in its execution [49]. The studies analyzed in the meta-analysis
are mostly randomized trials, which are those that offer the best evidence, but there are
scenarios where the information comes only from observational studies [50], as studies on
etiological hypotheses or adverse events. This represents a challenge as this type of design has
a higher risk of bias and lack of essential information for the integration of studies [51].
Furthermore, the inclusion of studies with a large heterogeneity or variability between them,
hinders the results interpretation [52], requires the knowledge of statistical tools for proper
interpretation [53] and one must know that it is a limitation for the applicability of the results.
Meta-analysis is a retrospective process, so it is susceptible to errors of this type of design. It
could have biases in any of its stages: in the search and selection of studies, analysis and
synthesis of information.
The meta-analysis is the highest level of evidence and summarizes the studies available about
a particular matter in a reliable way. Its implementation has its difficulties and limitations, so
methodological rigor is required to help reduce the risk of bias and a critical and cautious view
of its results.
As far as we know, two meta-analyses have been published regarding clinical implications of
CYP3A5 and CNIs in renal transplantation. One is about tacrolimus [54] and its conclusion
agrees with the data explained about CYP3A5 expressers/non-expressers dose requirements.
The other one deals with cyclosporine [55], and also concludes that there is an association
between our SNP and cyclosporine dose-adjusted concentration, where patients carrying
*3/*3 genotype will require a lower dose of the drug to reach target levels, compared with *1/
*1 or *1/*3 carriers.
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5.3. Barriers for the clinical application of Pharmacogenetics
The introduction in the medical practice of new strategies is always difficult, among other
reasons due to economic factors and the inertia of much of the professional sector, which is
typically conservative. But in the particular case of pharmacogenetics, and genomics in
general, there are other social factors that we will now comment, that hinder the implemen‐
tation of these new techniques.
Contrary to what has usually happened in other fields of biomedicine, in this one we have the
paradox that technological progress has gone faster than the advancement of knowledge.
Today’s technology platforms can just bring in a few days the data that used to take months
or even years to achieve. The advances in knowledge of the human genome sequence have
been really quick, especially since in February 2001 Nature and Science published simultane‐
ously the results of the Human Genome Project. The enormous progress in data collection
through technology could not be accompanied by a corresponding advance in the association
of the data with biological effects or implications for medical treatments [56]. A great amount
of research investment is still necessary in order to understand and take advantage of this huge
avalanche of data.
Clearly, every great discovery is preceded by circumstances that make it possible, and for the
deciphering of the human genome, and overall progress of genomics, including Pharmacoge‐
netics-omics, milestones were achieved with the confluence of three fundamental aspects: the
opportunity of high performance technologies (high throughput), the multidisciplinary
working groups and the development of bioinformatics.
Investment in technology and the big bet of different private companies have been crucial for
the rapid performance rate of genetic sequences data collection. In fact, as we have already
mentioned, more and more individual human sequences have been obtained, demonstrating
the variability of our genome and even small errors in the initial sequencing generations.
Anyway, such data cannot give us more information than little white dots on a blackboard,
with sometimes very specific information on diseases or even just some predispositions, but
little conclusive information for the moment. This is mainly due to two major keys in genetics
and biology: the first is that rarely a single gene is responsible for a disease, usually diseases
result from the interaction of many genes, with particular variants or defects. The second key
is that our phenotype is not an exclusive product of the expression of our genes, instead it is
the gene-environment combination. In most cases, the weight of each of the two components
in a given disease is difficult to decipher.
Moreover, not only the gene-environment relationship offers serious knowledge gaps, but also
the relationships between genes. Everyone knows that life is the result of Systems Biology, wa‐
terfalls of activation or repression of components that influence each other. That is the kind of
approach that we have to tend to, once we have more experience and results in reductionist
studies. Biological systems are complex networks of thousands of routes, many of which are in‐
terconnected, biosynthetic pathways, signal transduction pathways, routes of regulating the
expression of genes. The integration, representation and modeling of the interconnections of
biological information analysis require global, systemic analyses. This is how we enter the era
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of "omics" referring to global studies, "whole set", where we pass from the analysis of specific
phenomena to the search of the interrelationship of phenomena, where we must integrate not
only genomics but also proteomics (the sequences and expression patterns of all proteins), me‐
tabolomics (identification and quantification of all metabolites) and even transcriptomics (se‐
quences and expression patterns of all transcripts) and to close the circle, reach the interactome
(full set of physical interactions between proteins, DNA sequences and RNA). The review of T.
Manolio [57] is very useful for understanding the current situation of genomic studies.
In relation to this need for training and knowledge, we will introduce one of the biggest
problems facing the Pharmacogenetics and Pharmacogenomics application in our society: as
in any area of knowledge that directly affects Health and Drugs, clinical applications arising
from Pharmacogenetics should be well regulated and should be given proper use. Both the
patient and the doctor must be well informed of the scope and meaning of the data that can
be obtained. It is crucial to know what to expect of a pharmacogenetic analysis, realistically,
without creating false hopes.
It is said that in a couple of years, the cost for sequencing a complete human genome will be
about 1,000$. It is not difficult to imagine that there will soon be many patients who will consult
their physicians with their genome sequence in their hand, asking whether they will have
cancer or Alzheimer's or not, according to what is written in their genes. Are we prepared to
deal with these situations? The New England Journal of Medicine published a series of articles
and editorials addressing these issues on the occasion of the first decade of the publication of
the human genome, with very interesting articles written by experts in the field, as the great
review of Collins and coworkers [58].
And, if we are not prepared for this new tool yet, how will we discriminate between reliable
and fraudulent information? Who should be responsible for setting common guidelines to
drive us in making decisions about which tests are acceptable and which are not? We think
that the key are not only the regulatory agencies, which do not always agree with each other
when defining whether a marker is valid or not. However, other agents, Industry, and
especially the scientific societies, should be the ones to influence education on these issues and
serve as a reference under the most rigorous scientific method.
At the academic level, many efforts have been demanded to these disciplines because they
generated great expectations that were not met as fast as expected. Now, regulatory agencies
require a greater statistical significance than that of many other types of studies, to accept the
validity of a new marker. That is why well designed clinical studies and meta-analyses are
necessary for the agencies to accept new validated markers. We must also be aware of the
alarm triggered in relation to commercial proposals that are clearly misleading the consumer.
Just a quick search on the Internet to realize that they are on sale genotyping chips that offer
scientifically implausible predictions, such as predicting vulnerability to sudden death in
athletes, obesity, the ability to succeed at school, etc. The U.S. committee SACGHS (the
Secretary's Advisory Committee on Genetics, Health and Society) has already issued several
reports concerning with the issue and stressing the need to regulate this area of biomedicine
in order to not leave the consumer completely unprotected. There are two excellent publica‐
tions from Dr. JP Evans, illustrating this problem [59, 60].
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5.4. The economical impact
Pharmacogenetics must allow not only the money saving through the prevention of a large
number of side effects derived from the use of unsuitable drugs, but also it has to reduce the
money spending on unnecessary drugs. In the U.S. there is an incidence of adverse effects of
6.2-6.7% of hospitalized patients, representing two million adverse drug reactions per year
[61]. Of these, 0.15 to 0.3% are fatal, leading to about 100,000 deaths annually [62]. In Europe,
the data are similar.
Today, there are still few studies on the cost-effectiveness of pharmacogenetic studies,
although considerable efforts have been made, including regulatory authorities [63-65]. We
cannot forget that everyday genotyping platforms are more compact and economical and, as
mentioned, even the whole genome sequencing of a patient will have an assumable cost, so it
is not difficult to imagine that the benefits will overcome the costs and that the balance will be
tilted towards the realization of these studies [66]. A practical example is found in the studies
of mutations in the K-ras gene in colorectal cancer patients to decide about treatment with
Cetuximab, which are rendering large amounts of data regarding the savings thanks to the
genotyping of patients, avoiding ineffective treatment in 40% of cases.
In conclusion, the economical and clinical benefits of pharmacogenetics are day by day, clearly
surpassing its costs. We need to have especialized personnel, to help us know how to interpret
the pharmacogenetic information, always in close contact with clinicians and research
advances. We cannot obviate this new and real tool for the benefit of our patients’ health.
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